Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors
N/A
N/A
Both
Advanced Cancers
Trial Information
Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors
Study Groups:
If you are found to be eligible to take part in this study, your doctor will decide which
study drugs you will receive based on the disease type and the drugs you have taken in the
past
You will receive either a combination of pazopanib and lapatinib (Arm A) or a combination of
pazopanib and trastuzumab (Arm B).
Up to 5 dose levels of each combination will be tested. Up to 6 participants will be
enrolled at each dose level of each combination. The first group of participants will
receive the lowest dose level of each combination. Each new group(s) will receive a higher
combination than the group before it, if no intolerable side effects were seen. Participants
may be enrolled on 1-3 similar dose levels at the same time. You will be assigned to a dose
level based on when you joined this study. This will continue until the highest tolerable
dose(s) of the study drug combination is found.
The dose of the study drug combination that you receive may be lowered if you have
intolerable side effects.
Once the highest tolerable doses of the different combinations are found, this dose of each
combination will be given to an expansion group of 20 extra participants.
Study Drug Administration:
If you are in Arm A, you will take lapatinib by mouth 1 time each day. You will take
pazopanib by mouth 1 time every other day (Day 1, 3, 5, and so on). You should take
pazopanib and lapatinib either 1 hour before or 2 hours after eating a meal.
If you are in Arm B, you will take pazopanib by mouth 1 time each day. You will receive
trastuzumab by vein on Days 1, 8, 15, and 22 of each cycle. The first infusion will be over
90 minutes. If you handle the infusion well, the next infusions will be over 30 minutes.
You should take pazopanib either 1 hour before or 2 hours after eating a meal.
Each study cycle is 28 days.
Study Visits:
At all study visits, you will be asked about any drugs you may be taking and side effects
you may be having.
Week 3 of Cycle 1, blood (about 1 teaspoon) and urine will be collected for routine tests.
During Week 3 of Cycles 2 and beyond, blood (about 1 teaspoon) will be drawn for routine
tests.
During Week 4 of Cycle 2 and then every 2-3 cycles:
- You will have a CT scan, MRI scan, PET scan, and/or x-ray to check the status of the
disease.
- If the study doctor thinks it is needed, blood (about 1 teaspoon) will be drawn to
measure tumor markers.
Length of Study:
You may continue taking the study drugs for as long as the doctor thinks it is in your best
interest. You will be taken off study early if the disease gets worse, if you continue to
have intolerable side effects, or if you are unable to follow study directions.
Your participation on the study will be over once you have completed the end-of-study visit.
End-of-Study Visit:
Within 30 days after your last dose of study drugs, you will have an end-of-study visit. At
this visit, the following tests and procedures performed:
- Your medical history will be recorded.
- You will have a physical exam.
- You will be asked about any drugs you may be taking and side effects you may be having.
- Your weight, vital signs, and performance status will be recorded.
- Blood (about 2 teaspoons) and urine will be collected for routine tests.
- If the study doctor thinks it is needed, blood (about 1 teaspoon) will be drawn to
measure tumor markers.
- If the study doctor thinks it is needed, you will have a chest x-ray, CT scan, MRI
scan, and/or PET scan to check the status of the disease.
This is an investigational study. Pazopanib is FDA approved and commercially available for
the treatment of renal cell carcinoma. Lapatinib and trastuzumab are FDA approved and
commercially available for the treatment of breast cancer. The combination of pazopanib and
lapatinib or pazopanib and trastuzumab is investigational.
Up to 174 participants will take part in this study. All will be enrolled at MD Anderson.
Inclusion Criteria:
1. Patients with advanced cancer should be refractory to standard therapy, relapsed
after standard therapy, or have no standard therapy that improves survival by at
least three months.
2. Patients must have measurable or evaluable disease.
3. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status
4. Abnormal organ function is permitted; however, patients must have : Plt >/=100,000/,
ANC >/=1500, total Bilirubin Time/International Normalized Ratio/Partial Thromboplastin Time (PT/INR/PTT) within
1.5 X upper limit of normal (ULN).
5. A woman is eligible to enter and participate in the study if she is of
non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
including any female who has had a hysterectomy, bilateral oophorectomy
(ovariectomy), bilateral tubal ligation, is post-menopausal (total cessation of
menses for ≥ 1 year); OR if of childbearing potential, has a negative serum pregnancy
test at screening, and agrees to use adequate contraception.
6. A man with a female partner of childbearing potential is eligible to enter and
participate in the study if he uses a barrier method of contraception or abstinence
during the study.
7. Signed informed consent approved by the Institutional Review Board prior to patient
entry.
8. Expanded Cohort only: Patients must have HER2 amplification, HER2 mutation, c-Met
amplification, c-Met mutation, EML4-ALK translocation, or EGFR mutation.
Exclusion Criteria:
1. Poorly-controlled hypertension (systolic blood pressure [SBP] >/= 140 mmHg, or
diastolic blood pressure [DBP]>/= 90 mmHg).
2. Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled
diabetes,congestive cardiac failure )
3. History of myocardial infarction, admission for unstable angina, cardiac angioplasty
or stenting within three months of Day 1 of treatment period.
4. History of venous or arterial thrombosis within 3 months of Day 1 of treatment
Period.
5. Current use of therapeutic warfarin. NOTE: both low molecular weight heparin and
prophylactic low-dose warfarin are permitted; however, PT/PTT must meet above
inclusion criteria.
6. Excessive risk of bleeding or thrombosis as defined by stroke or severe bleeding
within the prior 6 months.
7. Patients who received investigational drugs, chemotherapy or immunotherapy patient
must be >/= five half-lives or >/= 3 weeks from the last dose of treatment, whichever
is shorter.
8. Any major surgery or radiotherapy within 14 days of treatment.
9. Patients with a documented Left Ventricular Ejection Fraction < 45%.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Maximum tolerated dose (MTD) of pazopanib in combination with lapatinib or trastuzumab
Outcome Description:
MTD is defined as highest dose in which incidence of dose limiting toxicity (DLT) was less than 33% (approximately two or more participants in a dose cohort).
Outcome Time Frame:
28 day cycle
Safety Issue:
Yes
Principal Investigator
David S. Hong, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UT MD Anderson Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
2011-0650
NCT ID:
NCT01454804
Start Date:
October 2011
Completion Date:
Related Keywords:
- Advanced Cancers
- Advanced Cancers
- Solid Tumors
- Pazopanib
- GW786034
- Lapatinib
- Tykerb
- GW572016
- Trastuzumab
- Herceptin
- Neoplasms
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
